Eptifibatide Adverse Events: What the Label and Studies Report

What Eptifibatide Is and Where It Is Given

Eptifibatide is a prescription medicine given as an intravenous infusion by specialist clinicians in a controlled clinical setting: hospital wards, cardiac catheterisation laboratories, coronary and intensive care units, and other monitored inpatient environments. It is not dispensed for self administration at home, and every decision about whether it is used, continued or stopped sits with the treating specialist team. Molecularly, it is a cyclic heptapeptide modelled on barbourin, a disintegrin isolated from snake venom, and a 2019 review traced the development of this class from venom disintegrins and C-type lectins into clinical antiplatelet drugs (PMID 31137917).

At label level, approved use covers acute coronary syndrome and patients undergoing percutaneous coronary intervention. Uses outside those approved indications, including the acute ischemic stroke settings described further down this page, are investigational. This page is for educational purposes only and is not medical advice; consult a licensed physician or the prescribing clinician about any symptom, any medicine and any treatment decision.

Boxed Warning Status

United States product labeling for eptifibatide does not carry a boxed warning. The absence of a boxed warning is a regulatory fact about the label format and is not a statement about how any individual patient will respond. The labeling still carries contraindications, warnings and precautions, and a list of adverse reactions, and the categories that dominate both the label and the published literature are bleeding and thrombocytopenia.

Serious Adverse Reactions: What Studies Report

Bleeding

Bleeding is the adverse event category most consistently described for this drug class. A 2011 review of the optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary intervention discussed bleeding risk as the central safety consideration governing how these agents are selected and monitored (PMID 21985168). A 2003 review of anti-integrin therapy similarly described haemorrhagic complications as the principal toxicity associated with blockade of the platelet integrin receptor (PMID 12414914). A broader overview of antiplatelet medications grouped bleeding as the defining adverse effect across antiplatelet agents and discussed monitoring and contraindications in that context (PMID 30725747).

Product labeling lists bleeding as the most common complication, including access site bleeding in patients undergoing arterial procedures, and identifies intracranial haemorrhage, retroperitoneal bleeding and gastrointestinal and genitourinary bleeding among serious events. Labeling also lists contraindications tied to bleeding risk, including a history of bleeding diathesis within the preceding 30 days, severe uncontrolled hypertension, major surgery within a recent window, a history of haemorrhagic stroke or recent stroke of any type, dependency on renal dialysis, and concomitant use of another parenteral glycoprotein IIb/IIIa inhibitor.

Thrombocytopenia

A 2021 case report in BMJ Case Reports described profound thrombocytopenia following eptifibatide exposure and characterised it as a rare complication requiring recognition and management by the treating team (PMID 34127501). The 2003 anti-integrin review placed thrombocytopenia alongside bleeding as a recognised adverse effect of agents targeting the glycoprotein IIb/IIIa receptor (PMID 12414914), and a 2011 review of novel antiplatelet agents discussed the same safety themes across the receptor antagonist class (PMID 22053759). Labeling instructs that platelet counts be monitored and lists acute profound thrombocytopenia among the reactions attributed to the drug.

Hypersensitivity

Product labeling describes hypersensitivity reactions, including anaphylaxis, among the events reported with eptifibatide, and lists known hypersensitivity to the drug or its components as a contraindication. Labeling notes that such reactions have been reported with initial exposure as well as with re-exposure. Any suspected allergic reaction is a matter for the clinicians administering the infusion.

Warnings and Precautions in the Labeling

Beyond bleeding, thrombocytopenia and hypersensitivity, the labeling for eptifibatide addresses several practical precautions that the specialist team manages directly. These include care with arterial and venous access sites, attention to concomitant medicines that affect haemostasis, and consideration of renal function because the drug is cleared renally. Labeling identifies dialysis dependence as a contraindication and addresses reduced renal function as a factor in product use.

Common Adverse Reactions: What Studies Report

In the pivotal programme summarised in the labeling, bleeding and hypotension were the adverse reactions reported more frequently with eptifibatide than with placebo, with minor bleeding and access site events making up a large share of the total. The reviews above described the same pattern across the glycoprotein IIb/IIIa class: a predominance of procedure related and access site bleeding, a smaller number of major haemorrhagic events, and thrombocytopenia occurring uncommonly but with clinical significance when it did (PMID 21985168, PMID 12414914).

Reported Events by Body System

Trial Findings in Specific Populations: What Studies Report

Acute ischemic stroke (investigational)

Use of eptifibatide in acute ischemic stroke is investigational rather than an approved indication. A 2024 randomised trial published in the New England Journal of Medicine evaluated adjunctive intravenous argatroban or eptifibatide added to thrombolytic treatment in patients with acute ischemic stroke, and researchers reported that neither adjunctive agent improved functional outcome compared with placebo while symptomatic intracranial haemorrhage and death were tracked as safety outcomes (PMID 39231343). A separate 2024 report in Neurology International examined low dose eptifibatide in patients with tandem occlusions treated for acute ischemic stroke, and the study was framed explicitly around safety as well as efficacy in that population (PMID 38392958).

Acute myocardial infarction and microvascular obstruction

The REVERSE-FLOW trial, published in the European Heart Journal in 2024, investigated glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction and angiographic microvascular obstruction, and researchers reported both efficacy and safety outcomes for that strategy (PMID 39217605). Trials of this kind sit alongside the class reviews that described bleeding as the dominant trade off when receptor blockade is intensified during coronary intervention (PMID 21985168).

Renal function

Because eptifibatide is cleared renally, the way kidney function is estimated matters to how patients with acute coronary syndromes are categorised. A 2008 analysis in the Journal of the American College of Cardiology compared the Cockcroft-Gault and Modification of Diet in Renal Disease formulas in patients with non-ST-segment elevation acute coronary syndromes and reported that the choice of formula changed chronic kidney disease classification, a distinction the authors connected to decisions about renally cleared antithrombotic agents (PMID 18325437).

Heart failure at baseline

A 2004 analysis in the American Heart Journal examined the benefits of glycoprotein IIb/IIIa inhibitors among patients who had heart failure at baseline during an acute coronary syndrome, and researchers reported outcomes for this higher risk subgroup separately from the broader trial population (PMID 14691424).

Overdose Reports: What Studies Report

A case report published in the International Journal of Cardiology described eptifibatide overdose and the clinical course and monitoring that followed in the hospital setting (PMID 18023892). Because the drug is administered only under direct clinical supervision, dosing, rate and duration are determined and adjusted by the treating specialist team, and this page carries no dosing, preparation or administration information.

How the Evidence Base Is Structured

The safety picture for eptifibatide rests on several different evidence types, and the strength of each differs. Randomised trials such as the 2024 stroke trial and REVERSE-FLOW generate comparative safety data within defined populations (PMID 39231343, PMID 39217605). Narrative and class reviews synthesise what trials across the receptor antagonist group have reported about bleeding and thrombocytopenia (PMID 21985168, PMID 22053759). Case reports, including the profound thrombocytopenia report and the overdose report, describe single patients and cannot establish how often an event occurs (PMID 34127501, PMID 18023892). Retrospective series such as the tandem occlusion report describe outcomes already recorded rather than outcomes assigned at random (PMID 38392958).

Where Questions Belong

Nothing on this page indicates whether eptifibatide is appropriate for any individual, and no statement here should be read as reassurance about risk. Symptoms that arise during or after an infusion, questions about bruising, bleeding, platelet counts, kidney function or allergic reactions, and any question about whether treatment should start, change or stop are matters for the prescribing clinician and the hospital team managing the infusion. Talk to your prescriber about any of these questions.

References

• Antiplatelet Medications (2022)
• From Snake Venom's Disintegrins and C-Type Lectins to Anti-Platelet Drugs (Toxins, 2019)
• Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke (The New England Journal of Medicine, 2024)
• Anti-integrin therapy (Annual Review of Medicine, 2003)
• Eptifibatide overdose (International Journal of Cardiology, 2009)
• Eptifibatide-induced profound thrombocytopaenia: a rare complication (BMJ Case Reports, 2021)
• Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial (European Heart Journal, 2024)
• Novel agents for anti-platelet therapy (Journal of Hematology & Oncology, 2011)
• Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions (Drugs, 2011)
• Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes (Journal of the American College of Cardiology, 2008)
• Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes (American Heart Journal, 2004)
• Safety and Efficacy of Low-Dose Eptifibatide for Tandem Occlusions in Acute Ischemic Stroke (Neurology International, 2024)